Triamcinolone acetonide hydrofluoroalkane intranasal - Meda

Drug Profile

Triamcinolone acetonide hydrofluoroalkane intranasal - Meda

Alternative Names: Nasacort HFA Nasal Aerosol; Triamcinolone acetonide HFA intranasal - Meda

Latest Information Update: 01 Apr 2015

Price : $50 *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Aventis
  • Class Anti-inflammatories; Antiallergics; Antiasthmatics; Antipsoriatics; Antirheumatics; Eye disorder therapies; Fluorinated steroids; Glucocorticoids; Pregnadienes; Small molecules
  • Mechanism of Action Immunosuppressants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity No

Highest Development Phases

  • Discontinued Perennial allergic rhinitis; Seasonal allergic rhinitis

Most Recent Events

  • 01 Apr 2015 Discontinued - Registered for Seasonal allergic rhinitis and Perennial allergic rhinitis in USA (Intranasal)
  • 21 Oct 2013 Acton Pharmaceuticals has been acquired by Meda
  • 08 Oct 2013 Biomarkers information updated
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top